Cosmo Pharmaceuticals N.V. 0RGI.L Stock
Cosmo Pharmaceuticals N.V. Price Chart
Cosmo Pharmaceuticals N.V. 0RGI.L Financial and Trading Overview
Cosmo Pharmaceuticals N.V. stock price | 69.44 CHF |
Previous Close | 47.72 CHF |
Open | 47.95 CHF |
Bid | 0 CHF x 0 |
Ask | 0 CHF x 0 |
Day's Range | 47.95 - 47.95 CHF |
52 Week Range | 42.75 - 69.4 CHF |
Volume | 15 CHF |
Avg. Volume | 1.52K CHF |
Market Cap | 7.06M CHF |
Beta (5Y Monthly) | 1.044444 |
PE Ratio (TTM) | 0.36743295 |
EPS (TTM) | 1.31 CHF |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0RGI.L Valuation Measures
Enterprise Value | 719.1M CHF |
Trailing P/E | 0.36743295 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.06919165 |
Price/Book (mrq) | 1.706345 |
Enterprise Value/Revenue | 7.044 |
Enterprise Value/EBITDA | 17.467 |
Trading Information
Cosmo Pharmaceuticals N.V. Stock Price History
Beta (5Y Monthly) | 1.044444 |
52-Week Change | 11.28% |
S&P500 52-Week Change | 20.43% |
52 Week High | 69.4 CHF |
52 Week Low | 42.75 CHF |
50-Day Moving Average | 52.06 CHF |
200-Day Moving Average | 56.64 CHF |
0RGI.L Share Statistics
Avg. Volume (3 month) | 1.52K CHF |
Avg. Daily Volume (10-Days) | 1.06K CHF |
Shares Outstanding | 15M |
Float | 8.69M |
Short Ratio | N/A |
% Held by Insiders | 47.28% |
% Held by Institutions | 11.66% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 1.05 |
Trailing Annual Dividend Yield | 2.20% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 16.87% |
Operating Margin (ttm) | 27.48% |
Gross Margin | 60.34% |
EBITDA Margin | 40.32% |
Management Effectiveness
Return on Assets (ttm) | 2.24% |
Return on Equity (ttm) | 3.58% |
Income Statement
Revenue (ttm) | 102.09M CHF |
Revenue Per Share (ttm) | 6.22 CHF |
Quarterly Revenue Growth (yoy) | 65.29% |
Gross Profit (ttm) | N/A |
EBITDA | 41.17M CHF |
Net Income Avi to Common (ttm) | 17.23M CHF |
Diluted EPS (ttm) | 1.305 |
Quarterly Earnings Growth (yoy) | -65.90% |
Balance Sheet
Total Cash (mrq) | 240.95M CHF |
Total Cash Per Share (mrq) | 14.82 CHF |
Total Debt (mrq) | 173.6M CHF |
Total Debt/Equity (mrq) | 37.43 CHF |
Current Ratio (mrq) | 1.57 |
Book Value Per Share (mrq) | 28.101 |
Cash Flow Statement
Operating Cash Flow (ttm) | 33.23M CHF |
Levered Free Cash Flow (ttm) | 11.7M CHF |
Profile of Cosmo Pharmaceuticals N.V.
Country | United Kingdom |
State | N/A |
City | Dublin |
Address | Riverside II |
ZIP | 2 |
Phone | 353 1 817 0370 |
Website | https://www.cosmopharma.com |
Industry | |
Sector(s) | |
Full Time Employees | 295 |
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, Parmascience Inc., RedHill Biopharma Ltd., Dr. Falk Pharma, Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Q&A For Cosmo Pharmaceuticals N.V. Stock
What is a current 0RGI.L stock price?
Cosmo Pharmaceuticals N.V. 0RGI.L stock price today per share is 69.44 CHF.
How to purchase Cosmo Pharmaceuticals N.V. stock?
You can buy 0RGI.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cosmo Pharmaceuticals N.V.?
The stock symbol or ticker of Cosmo Pharmaceuticals N.V. is 0RGI.L.
How many shares does Cosmo Pharmaceuticals N.V. have in circulation?
The max supply of Cosmo Pharmaceuticals N.V. shares is 147.31K.
What is Cosmo Pharmaceuticals N.V. Price to Earnings Ratio (PE Ratio)?
Cosmo Pharmaceuticals N.V. PE Ratio is 0.53210884 now.
What was Cosmo Pharmaceuticals N.V. earnings per share over the trailing 12 months (TTM)?
Cosmo Pharmaceuticals N.V. EPS is 1.31 CHF over the trailing 12 months.